Title
Authorize the Chief Executive Officer for Natividad Medical Center (NMC) or his designee to execute amendment No. 2 to the agreement (A-14125) with Monarch Medical Technologies, LLC, for the provision of glucose management system enterprise software subscriptions, adding the Endotool subcutaneous (subq) insulin dosing recommendation software license and subscription, with no changes to the agreement term of October 1, 2018 through January 31, 2025, and adding $182,783 for a revised total agreement amount not to exceed $459,824.
Report
RECOMMENDATION:
It is recommended the Board of Supervisors:
Authorize the Chief Executive Officer for Natividad Medical Center (NMC) or his designee to execute amendment No. 2 to the agreement (A-14125) with Monarch Medical Technologies, LLC, for the provision of glucose management system enterprise software subscriptions, adding the Endotool subcutaneous (subq) insulin dosing recommendation software license and subscription, with no changes to the agreement term of October 1, 2018 through January 31, 2025, and adding $182,783 for a revised total agreement amount not to exceed $459,824.
SUMMARY/DISCUSSION:
Endotool is a clinical decision support software that integrates with MEDITECH providing personalized recommendations for insulin therapy to better control the patient's glycemic rates in a more automated fashion. Our providers no longer choose from multiple order sets and instead use a Endotool management order. The nurse then follows the instructions from Endotool. The software is built using NMC's policies, procedures and protocols that define insulin management and glycemic control. Endotool has been proven to facilitate rapid glycemic control reducing hyper- and hypoglycemic events and improving patient outcomes and care.
NMC's current agreement with Monarch authorizes the use of the intravenous (IV) module that calculates insulin dosage for patients who are on an IV drip line. With this Amendment 2, NMC ...
Click here for full text